X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
adult (3) 3
female (3) 3
humans (3) 3
index medicus (3) 3
middle aged (3) 3
aged (2) 2
antibodies, monoclonal, humanized - adverse effects (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
breast cancer (2) 2
breast neoplasms - drug therapy (2) 2
breast neoplasms - mortality (2) 2
breast neoplasms - pathology (2) 2
chemotherapy (2) 2
disease-free survival (2) 2
dose-response relationship, drug (2) 2
drug administration schedule (2) 2
neoplasm invasiveness - pathology (2) 2
neoplasm staging (2) 2
oncology (2) 2
quinolines - administration & dosage (2) 2
quinolines - adverse effects (2) 2
risk assessment (2) 2
trastuzumab (2) 2
treatment outcome (2) 2
tyrosine kinase (2) 2
adenoid cystic (1) 1
adenoid cystic carcinoma (1) 1
adjuvant chemotherapy (1) 1
administration, oral (1) 1
advanced tumors (1) 1
aged, 80 and over (1) 1
anthracyclines - adverse effects (1) 1
anthracyclines - therapeutic use (1) 1
antibodies, monoclonal, humanized (1) 1
antibodies, monoclonal, humanized - therapeutic use (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic combined chemotherapy protocols (1) 1
antineoplastic combined chemotherapy protocols - administration & dosage (1) 1
antineoplastic combined chemotherapy protocols - pharmacokinetics (1) 1
antineoplastic combined chemotherapy protocols - pharmacology (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
arq 197 (1) 1
article (1) 1
biomarkers - blood (1) 1
biotechnology (1) 1
breast cancer classification (1) 1
breast neoplasms (1) 1
breast neoplasms - surgery (1) 1
c-met protooncogene (1) 1
cancer (1) 1
cancer therapies (1) 1
cardiac & cardiovascular systems (1) 1
cardiac function (1) 1
cardio-oncology (1) 1
cardiotoxicity (1) 1
cardiovascular (1) 1
chemotherapy, adjuvant (1) 1
chemotherapy, combination (1) 1
clinical trial, phase iii (1) 1
clinical trials (1) 1
cohort studies (1) 1
comparative study (1) 1
cribriform (1) 1
cytochrome p-450 cyp2c19 - genetics (1) 1
digestive system diseases (1) 1
disease (1) 1
distant recurrence (1) 1
dose-escalation (1) 1
double-blind method (1) 1
doxorubicin (1) 1
drug therapy (1) 1
dual cell population (1) 1
endocrine therapy (1) 1
epidemiology (1) 1
erbb-2 protein (1) 1
estrogen (1) 1
estrogen receptor negative (1) 1
estrogen-receptor (1) 1
excellent prognosis (1) 1
follow-up (1) 1
follow-up studies (1) 1
heart failure (1) 1
heart failure - blood (1) 1
heart failure - chemically induced (1) 1
heart failure - mortality (1) 1
heart failure - pathology (1) 1
hepatocellular-carcinoma (1) 1
hepatocyte growth-factor (1) 1
hera trial (1) 1
heregulin (1) 1
high-dose chemotherapy (1) 1
inhibitor drugs (1) 1
invasive cribriform carcinoma (1) 1
japan (1) 1
joint analysis (1) 1
journal article (1) 1
kaplan-meier estimate (1) 1
lapatinib (1) 1
local recurrence (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Martin, Miguel and Holmes, Frankie A and Ejlertsen, Bent and Delaloge, Suzette and Moy, Beverly and Iwata, Hiroji and von Minckwitz, Gunter and Chia, Stephen K L and Mansi, Janine and Barrios, Carlos H and Gnant, Michael and Tomašević, Zorica and Denduluri, Neelima and Šeparović, Robert and Gokmen, Erhan and Bashford, Anna and Ruiz Borrego, Manuel and Kim, Sung-Bae and Kim, Seung Jin and Jakobsen, Erik Hugger and Ciceniene, Audrone and Inoue, Kenichi and Overkamp, Friedrich and Heijns, Joan B and Armstrong, Anne C and Link, John S and Joy, Anil Abraham and Bryce, Richard and Wong, Alvin and Moran, Susan and Yao, Bin and Xu, Feng and Xu, Binghe and Auerbach, Alan and Buyse, Marc and Chan, Arlene and Harvey, Vernon and Tomek, Rudolf and Robert, Nicholas J and Gore, Ira and Smith, John W and Smith, Julie C and Masuda, Norikazu and Di Sean Kendall, S and Harker, William Graydon and Petrakova, Katarina and Guerrero Zotano, Angel and Simon, Amparo Ruiz and Konstantinovic, Zora Neskovic and Iannotti, Nicholas O and Tassone, Pierfrancesco and Rodriguez, Gladys I and Jáñez Martinez, Noelia and Crespo Massieu, Carmen and Smickoska, Snezana and Somali, Isil and Yilmaz, Ugur and Alonso, Mirta Garcia and Rosales, Adolfo Murias and Cold, Soeren and Knoop, Ann Soegaard and Patt, Debra and Hellerstedt, Beth A and Morales Murillo, Serafin and Mayer, Ingrid A and Means-Powell, Julie Ann and Hui, Rina and Senecal, Francis M and De Boer, Richard Hendry and Shen, Zhenzhou and Luczak, Adam Andrzej and Chui, Joanna W.Y and Chui, Stephen and Tsang, Janice Wing-hang and Lang, Istvan and Rai, Yoshiaki and Hozumi, Yasuo and Ten Tije, Albert J and Bhandari, Manish and Osborne, Cynthia R.C and Ohtani, Shoichiro and Higaki, Kenji and Watanabe, Junichiro and Watanabe, Kenichi and Taguchi, Tetsuya and Taguchi, Kazunori and Takahashi, Masato and Filipovic, Sladjana and Hansen, Vincent L and Rao, Vijayarama Phooshkooru and Gupta, Manish and Petrov, Petar and Coudert, Bruno and Vojnovic, Zeljko and Polya, Zsofia and Miyaki, Toshiko and Yamamoto, Naohito and Brincat, Stephen and Lesniewski-Kmak, Krzysztof and Chmielowska, Ewa and ... and ExteNET Study Grp and ExteNET Study Group
The Lancet Oncology, ISSN 1470-2045, 12/2017, Volume 18, Issue 12, pp. 1688 - 1700
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2013, Volume 31, Issue 26_suppl, pp. 8 - 8
Journal Article
Investigational New Drugs, ISSN 0167-6997, 2/2015, Volume 33, Issue 1, pp. 159 - 168
Purpose This phase I study evaluated the safety, tolerability, maximum tolerated dose (MTD), and recommended phase II dose (RP2D) of tivantinib combined with... 
Medicine & Public Health | Sorafenib | VEGF inhibition | Phase I trial | Oncology | Advanced tumors | MET RTK inhibition | Pharmacology/Toxicology | Tivantinib | TYROSINE KINASE | HEPATOCYTE GROWTH-FACTOR | C-MET PROTOONCOGENE | ARQ 197 | RENAL-CELL CARCINOMA | DOSE-ESCALATION | LUNG-CANCER | HEPATOCELLULAR-CARCINOMA | SELECTIVE INHIBITOR | ONCOLOGY | THERAPEUTIC TARGET | PHARMACOLOGY & PHARMACY | Neoplasms - metabolism | Niacinamide - analogs & derivatives | Proto-Oncogene Proteins c-met - metabolism | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Pyrrolidinones - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Quinolines - administration & dosage | Quinolines - pharmacology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Pyrrolidinones - administration & dosage | Quinolines - pharmacokinetics | Young Adult | Neoplasms - genetics | Phenylurea Compounds - adverse effects | Pyrrolidinones - pharmacology | Aged, 80 and over | Niacinamide - pharmacokinetics | Adult | Female | Phenylurea Compounds - pharmacokinetics | Pyrrolidinones - adverse effects | Niacinamide - adverse effects | Cytochrome P-450 CYP2C19 - genetics | Treatment Outcome | Neoplasms - drug therapy | Niacinamide - administration & dosage | Polymorphism, Genetic | Maximum Tolerated Dose | Phenylurea Compounds - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Phenylurea Compounds - pharmacology | Niacinamide - pharmacology | Quinolines - adverse effects | Chemotherapy, Combination | Usage | Research | Drug therapy | Tumors | Studies | Clinical trials | Inhibitor drugs | Pharmaceutical sciences | Index Medicus | Phase I Studies
Journal Article
Journal of Cardiac Failure, ISSN 1071-9164, 2013, Volume 19, Issue 1, pp. 10 - 15
Abstract Background Breast cancer (BC) treatments can cause heart failure (HF) in a subset of patients. ACC/AHA guidelines classify patients receiving... 
Cardiovascular | neuregulin | cardiotoxicity | cardio-oncology | Cardiac function | ADJUVANT CHEMOTHERAPY | CARDIAC & CARDIOVASCULAR SYSTEMS | RISK-FACTORS | DOXORUBICIN | TROPONIN-I | THERAPY | DISEASE | PHYSICAL-ACTIVITY | HIGH-DOSE CHEMOTHERAPY | OUTCOMES | PLUS | Anthracyclines - adverse effects | Predictive Value of Tests | Prognosis | Prospective Studies | Humans | Middle Aged | Antineoplastic Agents - administration & dosage | Heart Failure - blood | Dose-Response Relationship, Drug | Neuregulins - blood | Antineoplastic Agents - adverse effects | Neoplasm Invasiveness - pathology | Statistics, Nonparametric | Adult | Female | Neuregulins - metabolism | Heart Failure - mortality | Severity of Illness Index | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Drug Administration Schedule | Risk Assessment | Stroke Volume - drug effects | Survival Rate | Biomarkers - blood | Heart Failure - pathology | Breast Neoplasms - drug therapy | Disease-Free Survival | Breast Neoplasms - pathology | Breast Neoplasms - mortality | Aged | Anthracyclines - therapeutic use | Neoplasm Staging | Heart Failure - chemically induced | Trastuzumab | Cohort Studies | Heart failure | Medical colleges | Chemotherapy | Breast cancer | Cancer | Index Medicus | cardiac function | heregulin
Journal Article
02/2012, ISBN 9781118083734, 8
Adenoid cystic carcinoma of the breast, when properly and rigidly defined, accounts for about 0.1% of all invasive breast malignancies. Strict criteria were... 
Breast cancer classification | Distant recurrence | Invasive cribriform carcinoma | Local recurrence | Epidemiology | Adenoid cystic carcinoma | Primary tumors
Book Chapter
05/2006, ISBN 9780470012024, 7
Adenoid cystic carcinoma (ACC) of the breast is a special type of breast cancer that, when properly and rigidly defined, accounts for about 0.1% of all... 
myoepithelial cells | excellent prognosis | estrogen receptor negative | special type | dual cell population | Adenoid cystic | cribriform | Myoepithelial cells | Estrogen receptor negative | Cribriform | Dual cell population | Special type | Excellent prognosis
Book Chapter
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.